Kurs
-5,00%
Likviditet
1,60 MNOK
Prenumeration
Kalender
Est. tid* | ||
2025-08-28 | - | Kvartalsrapport 2025-Q2 |
2025-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2025-06-05 | - | Årsstämma |
2025-04-10 | - | Bokslutskommuniké 2024 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-19 | - | Årsstämma |
2024-06-06 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2024-04-25 | - | Bokslutskommuniké 2023 |
2023-10-04 | - | Split CRNA 30:1 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-22 | - | Årsstämma |
2023-04-21 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2023-03-09 | - | Extra Bolagsstämma 2023 |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-11-03 | - | Kvartalsrapport 2022-Q3 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-04-20 | - | Årsstämma |
2022-04-07 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2022-02-17 | - | Bokslutskommuniké 2021 |
2021-11-25 | - | Extra Bolagsstämma 2021 |
2021-11-04 | - | Kvartalsrapport 2021-Q3 |
2021-08-18 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | Kvartalsrapport 2021-Q1 |
2021-03-18 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2021-03-17 | - | Årsstämma |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-05 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-07 | - | Kvartalsrapport 2020-Q1 |
2020-04-30 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2020-04-29 | - | Årsstämma |
2020-03-11 | - | Bokslutskommuniké 2019 |
2019-11-07 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-09 | - | Kvartalsrapport 2019-Q1 |
2019-04-10 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2019-04-09 | - | Årsstämma |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-01 | - | Kvartalsrapport 2018-Q3 |
2018-08-23 | - | Kvartalsrapport 2018-Q2 |
2018-05-03 | - | Kvartalsrapport 2018-Q1 |
2018-04-12 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2018-04-11 | - | Årsstämma |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-11-16 | - | Kvartalsrapport 2017-Q3 |
2017-08-24 | - | Kvartalsrapport 2017-Q2 |
2017-04-25 | - | Kvartalsrapport 2017-Q1 |
2017-04-05 | - | Årsstämma |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-11-17 | - | Kvartalsrapport 2016-Q3 |
2016-08-25 | - | Kvartalsrapport 2016-Q2 |
2016-05-12 | - | Kvartalsrapport 2016-Q1 |
2016-04-14 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2016-04-13 | - | Årsstämma |
2015-06-23 | - | X-dag ordinarie utdelning CRNA 0.00 NOK |
2015-06-22 | - | Årsstämma |
Beskrivning
Land | Norge |
---|---|
Lista | Oslo Bors |
Sektor | Hälsovård |
Industri | Bioteknik |
The Financial Supervisory Authority of Norway (Nw.: Finanstilsynet) has today approved a securities note, a registration document and a summary (together referred to as the "Prospectus"), which prepares for potential future share issues and conversions of bonds under the bond terms and the Investment Agreement with Atlas Special Opportunities LLC and Atlas Capital Markets LLC.
The Prospectus is available on the Company’s website: https://www.circio.com/en/section/investors/prospectus/
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com
About Circio
Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing powerful circular RNA vector expression technology for next generation nucleic acid medicine.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.
In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc.